Back to search results

STEP Platform for Acute Ischemic Stroke

This study, called STEP, is for people who have had an acute ischemic stroke (a stroke caused by a blood clot) due to a blockage in a large or medium blood vessel in the brain. It compares different ways to treat these strokes. You might receive endovascular thrombectomy (a procedure to remove the clot using a device like a Neurovascular Mechanical Thrombectomy Device or a Catheter, Thrombus Retriever) or medical management (which can include medications like those for dissolving clots, antiplatelets, blood pressure, or cholesterol, and rehabilitation). The main goal is to see how these treatments affect your global disability 90 days after the stroke, using a measure called the Modified Rankin Score. This study is looking for 1600 participants aged 18 and older who are suspected of having this type of stroke. The current status of the study is unclear.

Study design
This is a randomized, multifactorial, adaptive platform trial. It is designed to compare different treatments for acute ischemic stroke.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your global disability will be measured 90 days after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06289985

StrokeNet Thrombectomy Endovascular Platform

Recruiting
NAAges 18+InterventionalTreatment
Medical University of South Carolina
~1,600 participants
Updated 2025-12-04 on ClinicalTrials.gov
What's tested:Endovascular thrombectomy with any FDA-approved category POL or NRY deviceMedical Management

At a glance

Recruiting sites
41 of 41 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Global disability measured by Modified Rankin Score
Measured over 90-day

Conditions

Ischemic Stroke

Explore related trials

Ischemic Stroke

Where it's being run

41 sites across 21 states
California5
New York5
Ohio4
Pennsylvania3
Texas3
Connecticut2
Florida2
Massachusetts2

Study leadership

  • Jordan J Elm, PhD · PRINCIPAL_INVESTIGATOR · Medical University of South Carolina
  • Eva A Mistry, MBBS, MSCI · PRINCIPAL_INVESTIGATOR · University of Cincinnati
  • Pooja Khatri, MD · PRINCIPAL_INVESTIGATOR · University of Cincinnati
  • Colin P Derdeyn, MD · PRINCIPAL_INVESTIGATOR · University of Virginia
  • Jeffery L Saver, MD · PRINCIPAL_INVESTIGATOR · University of California, Los Angeles
  • Tudor G Jovin, MD · PRINCIPAL_INVESTIGATOR · The Cooper Health System
  • Raul G Nogueira, MD, FAHA · PRINCIPAL_INVESTIGATOR · University of Pittsburgh
  • David Fiorella, MD, PhD · PRINCIPAL_INVESTIGATOR · Stony Brook University
  • Adnan Siddiqui, MD, PhD · PRINCIPAL_INVESTIGATOR · University at Buffalo
  • J Mocco, MD, MS · PRINCIPAL_INVESTIGATOR · MOUNT SINAI HOSPITAL

Who to contact

Jordan Elm
[email protected]
843-876-1605
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Global disability measured by Modified Rankin Score90-day

    The modified Rankin Score is a 7-outcome ordinal scale where 0 = No symptoms and 6= Dead. The analysis of the primary endpoint will be based on a utility weighting of the 7 outcomes, where 0 represents the worst possible health state and 1 represents the best possible state.